Scientists have uncovered extensive insights into how genetic mutations drive severe autism, opening the door to drug‑testing opportunities for treating the condition, a new study reports.
The team mapped how these mutations alter protein interactions within cells, influencing brain development.
“This is making maps of unknown territories that’s really necessary to move the biology forward,” said Dan Geschwind, a neurogeneticist at the University of California, Los Angeles, who was not involved in the study.
Research into autism dates back more than eight decades, yet only recently have scientists been able to delve into its molecular underpinnings. A major barrier to progress has been the fact that autism encompasses a wide spectrum of conditions rather than a single disorder.
Individuals with autism may struggle with language and social interaction and frequently exhibit repetitive behaviors. While many diagnosed individuals achieve independence in adulthood, others remain nonspeaking, face intellectual challenges, and need full‑time care.
However, roughly 30% of autism cases—particularly those with the most severe symptoms—are linked to single‑gene mutations that are almost certain to cause the condition.
Since these genes began to emerge about two decades ago, researchers hoped to develop targeted therapies for severe autism. Early experiments in mice carrying the mutations tested various drugs to reverse autism‑like behaviors, yet no effective gene‑specific treatment has yet materialized.
Matthew State, a psychiatrist at the University of California, San Francisco, and a coauthor of the study, emphasized that a deeper understanding of how mutations affect the brain is essential before effective autism drugs can be designed.
“There’s a huge missing step,” Dr. State noted. “The genes are building proteins that drive cellular biology.”
Many autism researchers are now working to close this gap. For instance, Dr. Geschwind’s team investigates gene activation patterns in neurons bearing autism‑linked mutations, while Dr. State’s group examines the functions of the proteins those genes encode.
Cellular proteins rarely act in isolation; their functions depend on interactions with other proteins. In this study, Dr. State and collaborators selected 100 autism‑associated proteins and identified their molecular partners.
They introduced each protein into cultured cells, enabling it to bind interacting partners, and then isolated the autism proteins together with any associated binding partners.
This approach uncovered over 1,000 partner proteins associated with the 100 autism‑linked proteins.
Numerous previously unknown interactions were identified. “There is a huge amount here for people to follow up,” said Jonathan Sebat, a geneticist at UC San Diego, who was not involved in the study.
Subsequent experiments showed that autism‑linked mutations alter protein interaction dynamics. Some mutations increase binding affinity, making proteins “stickier,” while others reduce it, causing proteins to dissociate more readily.
Researchers suspect these interaction changes disrupt neuronal development. “I believe these are drivers of the disease,” said Nevan Krogan, a molecular biologist at UCSF and a coauthor of the study.
To test this hypothesis, the team examined specific mutations in detail, including the FOXP1 and FOXP4 genes, which are active during brain development. Under normal conditions, the corresponding proteins bind together and activate genes that promote cell division and the generation of new brain cells.
An autism‑associated mutation alters the structure of FOXP1, eliminating the molecular “glue” that normally holds it and FOXP4 together, according to Dr. Krogan’s team.
FOXP1 alone continues to activate genes essential for typical brain development, but the freed FOXP4 protein “goes rogue,” Dr. Krogan explained.
The misregulated FOXP4 binds to genes that should remain silent and activates them, preventing proper cell division—a process Dr. Krogan and his collaborators propose contributes to autism pathology.
“That’s exactly the kind of mechanistic connection we want to see,” Dr. Sebat remarked.
These detailed mechanistic insights suggest potential therapeutic strategies, such as using a small molecule to restore the FOXP1‑FOXP4 interaction or preventing the rogue FOXP4 from binding DNA.
A drug that corrects the FOXP1 defect might only benefit patients carrying that specific mutation, implying that severe autism treatments could require a drug for each distinct molecular abnormality. Ongoing clinical trials are already pursuing mutation‑specific genetic therapies.
Dr. State counters that the challenge may be overstated, as many of the 100 autism‑linked proteins share common interaction partners, indicating they operate within shared cellular networks.
“We’re not pulling out random things,” Dr. State emphasized. “They’re biologically coherent.”
Little is understood about the genetics of milder autism, and some autistic individuals regard the condition as a natural variation rather than a disorder requiring treatment. For those with severe disabilities and their families, however, the study’s discovery of shared molecular pathways raises hope that a single therapy could benefit multiple genetic causes of severe autism.
“The most exciting finding is that diverse mutations converge on the same molecular pathways,” said Alison Singer, director of the Autism Science Foundation and mother of a 29‑year‑old daughter with profound autism.
She added that the discovery could unite families with varied genetic mutations as well as those without a known cause, noting, “What it says is that you may not need a separate therapeutic strategy for each gene.”
Other experts, however, contend that the study lacks sufficient evidence to confirm common networks in autism. “Those are weak claims,” Dr. Sebat observed.
Nonetheless, Joseph Buxbaum, a neuroscientist at the Icahn School of Medicine at Mount Sinai, suggested that any overlap among autism mutations could advance treatment efforts. “If it works at all, we’ll be very happy,” he remarked.